marasco
human
mous
antiidiotyp
monoclon
antibodi
therapeut
potenti
germlin
genebas
bcll
mab
case
chronic
lymphocyt
leukemia
bcell
phenotyp
bcll
germlin
util
vh
gene
b
cell
receptor
bcr
mous
antiidiotyp
monoclon
antibodi
discov
screen
rheumatoid
factor
rf
bind
high
affin
idiotop
express
allel
germlin
gene
encod
antibodi
c
find
unmut
encod
bcr
frequent
express
bcll
cell
provid
opportun
antiidiotyp
monoclon
antibodi
immunotherapi
studi
first
show
deplet
b
cell
encod
bcr
use
novel
human
gtl
mous
model
next
human
demonstr
human
antibodi
especi
display
higher
bind
affin
c
antibodi
compar
parent
addit
studi
show
abl
kill
c
bcr
express
cell
patient
bcll
cell
antibodydepend
cellmedi
cytotox
adcc
complementdepend
cytotox
cdc
final
mediat
vivo
deplet
bcll
cell
nsg
mice
data
suggest
may
provid
new
precis
medicin
select
kill
c
bcll
cell
bcell
chronic
lymphocyt
leukemia
bcll
common
leukemia
unit
state
account
approxim
adult
leukemia
case
individu
develop
bcll
annual
circa
death
cur
therapi
small
molecul
inhibitor
btk
inhibitor
famili
inhibitor
well
purin
nucleosid
analog
pna
use
standard
treatment
bcll
patient
shown
respons
rate
rang
howev
treatment
agent
invari
associ
side
effect
rang
mild
sever
eventu
emerg
drug
resist
addit
immunotherapi
bcll
includ
ofatumumab
arzerra
rituximab
rituxan
alemtuzumab
campath
show
common
caveat
target
cell
surfac
marker
indistinct
express
normal
malign
b
cell
poorli
express
bcll
cell
therefor
immedi
need
altern
therapi
specif
toward
malign
cell
bcll
patient
one
characterist
bcll
b
cell
receptor
bcr
shown
bias
immunoglobulin
ig
heavi
chain
ighv
usag
addit
current
understand
patholog
mechan
involv
bcll
suggest
two
distinct
subgroup
patient
base
absenc
presenc
somat
mutat
variabl
region
ighv
gene
estim
half
bcll
case
express
variabl
heavi
chain
vh
gene
mutat
compar
patient
vh
germlin
gene
sequenc
wherea
half
express
essenti
unmut
vh
gene
deviat
germlin
sequenc
patient
unmut
vh
gene
distinctli
aggress
malign
diseas
much
shorter
surviv
rate
addit
high
proport
ighvunmut
bcll
case
often
carri
complementaritydetermin
region
cdr
stereotyp
rearrang
v
j
segment
bias
germlin
gene
usag
stereotyp
vh
rearrang
present
highli
restrict
set
bcr
may
serv
distinct
immunolog
marker
tumorassoci
antigen
target
immunotherapi
contact
wayn
marasco
waynemarasco
dfciharvardedu
author
contribut
equal
work
present
address
abvitro
inc
boston
usa
germlin
gene
among
first
gene
shown
overrepres
bcll
patient
unmut
ighv
gene
highest
frequenc
stereotyp
v
h
h
j
h
rearrang
sever
studi
report
bcll
patient
overexpress
encod
bcr
leukem
cell
locu
show
extens
allel
polymorph
evid
gene
duplic
delet
allel
broadli
character
belong
either
allel
group
individu
util
one
copi
either
allel
group
bcr
express
allel
germlin
gene
distinctli
express
bcr
bcll
cell
murin
heavi
chain
direct
idiotyp
antibodi
gener
affect
structur
idiotyp
c
express
eight
allel
six
allel
germlin
gene
differ
residu
one
residu
framework
frw
preferenti
recogn
antibodi
encod
allel
express
germlin
configur
particularli
sensit
amino
acid
substitut
distinctli
hydrophob
loop
sinc
circa
circul
igh
repertoir
healthi
individu
express
bcr
anticanc
reagent
target
b
cell
subset
lead
global
b
cell
deplet
therefor
offer
potenti
new
precis
medicin
select
therapeut
agent
aggress
subset
bcll
studi
report
human
experi
perform
investig
therapeut
potenti
immunodeplet
malign
b
cell
bcll
patient
util
bcr
potent
human
antibodi
show
higher
bind
affin
parent
exhibit
potent
kill
activ
multipl
c
express
cell
human
bcll
tumor
cell
vitro
human
mous
model
vivo
determin
could
mediat
vivo
deplet
c
express
lymphocyt
util
gtl
mous
model
nodcgprkdc
scid
szj
nsg
mice
engraft
human
fetal
bone
marrow
liver
thymu
tissu
gener
human
immun
investig
vivo
immunodeplet
activ
reconstitut
b
cell
popul
first
peripher
blood
gtl
mice
stain
human
c
mononuclear
cell
week
post
immun
reconstruct
verifi
level
engraft
gtl
mice
randomli
assign
differ
group
treat
control
antibodi
seven
day
treatment
mous
blood
harvest
analyz
serum
level
well
total
c
b
cell
popul
c
b
cell
fluorescenceactiv
cell
sort
fac
serum
level
day
ngml
respect
correct
background
bind
normal
mous
serum
fig
shown
fig
treatment
result
chang
total
bcell
popul
howev
c
b
cell
subpopul
dramat
decreas
mice
compar
group
fig
possibl
result
could
due
satur
allel
encod
bcr
serum
unlik
day
serum
level
nm
significantli
equilibrium
dissoci
constant
k
idiotyp
discuss
moreov
express
cognat
igm
igg
c
antibodi
plasma
control
iggtreat
mice
markedli
decreas
day
fig
day
fig
dramat
loss
c
b
cell
loss
allel
encod
igm
igg
mous
plasma
demonstr
capac
deplet
c
b
cell
vivo
heavi
light
chain
variabl
region
vh
vl
gene
hybridoma
cell
line
individu
recov
rtpcr
use
specif
primer
mous
antibodi
variabl
gene
vh
vl
belong
mous
v
h
j
h
h
v
k
j
k
segment
respect
fig
next
structureguid
cdr
graft
approach
employ
human
select
human
acceptor
frw
templat
cdrgraft
vh
vl
amino
acid
sequenc
separ
compar
human
antibodi
sequenc
imgt
databas
identifi
similar
human
antibodi
ig
germlin
vh
vl
sequenc
bestmatch
human
ig
germlin
v
sequenc
homolog
homolog
use
igg
protein
sequenc
blast
compar
human
human
monoclon
antibodi
mab
includ
fab
antitissu
factor
antimusk
odor
traseolid
mous
fab
antidna
photoproduct
reveal
variabl
degre
sequenc
homolog
subsequ
fab
structur
pdbid
chosen
templat
vh
chain
sequenc
ident
similar
frw
residu
vh
chain
unchang
cdr
mutat
reflect
cdr
closer
examin
modifi
structur
reveal
major
steric
clash
addit
structur
chosen
templat
vl
chain
sequenc
ident
similar
sequenc
analysi
structur
reveal
one
steric
clash
replac
human
final
human
design
multipl
sequenc
align
clustalx
conserv
fwr
residu
addit
manual
exchang
residu
vh
vl
fwr
consensu
human
germlin
sequenc
gener
version
sequenc
align
amino
acid
shown
fig
amino
acid
mutat
vh
vl
respect
abinitio
gener
homolog
model
use
identifi
surfac
access
solvent
expos
residu
via
wam
server
visual
deepview
program
swisspdbview
http
wwwexpasyorgspdbv
fig
residu
ident
human
germlin
sequenc
fwr
region
insilico
mutat
perform
via
pymol
mutagenesi
tool
replac
framework
residu
mous
human
sequenc
delano
scientificwwwpymolorg
gromo
forc
field
energi
minim
paramet
appli
homolog
model
use
deepview
program
default
set
display
certain
residu
high
entropi
side
chain
rotam
fig
examin
energi
minim
homolog
model
reveal
residu
distort
geometri
steric
clash
residu
anomali
upon
closer
examin
either
distort
geometri
steric
clash
visual
pymol
fig
right
summari
four
identifi
residu
mutat
back
origin
mous
residu
includ
one
residu
vh
three
residu
vl
creat
version
furthermor
test
contribut
threonin
mous
germlin
vh
chain
oppos
lysin
human
germlin
bind
target
bind
affin
variant
antibodi
c
mab
human
vh
vl
gene
variant
de
novo
synthes
codonoptim
mammalian
cell
express
bind
affin
scfvfc
c
igg
analyz
elisa
result
fig
show
lost
bind
abil
howev
exhibit
even
better
bind
affin
parent
next
use
biacor
interrog
bind
kinet
scfvfc
scfv
shown
fig
fig
interestingli
one
residu
differ
influenc
bind
affin
suggest
definit
role
lysin
modul
bind
pattern
insilico
model
suggest
residu
steric
clash
thu
back
mutat
mous
residu
fig
howev
result
loss
affin
albeit
small
indic
may
caus
subtl
chang
bind
site
posit
conform
enabl
increas
bind
affin
result
show
human
success
better
bind
affin
bind
higher
affin
two
antibodi
unmut
vh
segment
three
encod
scfv
one
control
encod
scfv
investig
bind
affin
use
meso
scale
discoveri
msd
immunoassay
interestingli
bound
strongli
scfv
ident
germlin
gene
compar
ident
reactiv
scfv
fig
test
bind
affin
sensor
system
use
measur
associ
dissoci
kinet
encod
scfvfc
coat
sa
sensor
tip
surfac
fig
octetr
assay
result
show
specif
bind
encod
scfvfc
wherea
bind
control
scfvfc
moreov
slower
kon
bind
germlin
compar
scfvfc
circa
slower
koff
result
increas
bind
affin
result
provid
addit
support
specif
bind
encod
immunoglobulin
higher
affin
bind
unmut
allel
delin
biolog
mechan
treatment
caus
deplet
c
b
cell
cdc
adcc
assay
perform
mimic
c
bcll
cell
use
encod
scfv
fig
show
ident
germlin
gene
respect
construct
c
cell
transfect
fig
anchor
surfaceexpress
c
scfv
cell
membran
scfvfc
protein
fuse
frame
transmembran
moieti
follow
transfect
effici
zsgreen
coexpress
bicistron
messag
visual
fluoresc
microscop
fig
surfac
express
c
antibodi
analyz
fac
stain
allophycocyanin
apc
conjug
zsgreen
fig
transduc
cell
use
target
cell
cdc
adcc
assay
scfvfc
evalu
capac
mediat
cdc
activ
c
cell
use
rabbit
serum
shown
fig
c
circa
target
cell
kill
treat
exhibit
slightli
better
potent
cdc
activ
three
c
cell
compar
cdc
activ
specif
cdcmediat
kill
shown
lack
cytotox
neg
control
cell
fig
test
activ
mous
antihuman
fc
show
kill
activ
among
transduc
cell
fig
subsequ
focus
alon
evalu
adcc
activ
shown
fig
c
maintain
potent
adcc
activ
three
c
cell
line
mgml
variabl
kill
activ
compar
lower
antibodi
concentr
neither
kill
neg
control
cell
adcc
fig
mous
antihuman
fc
use
adcc
assay
show
kill
activ
transduc
cell
fig
mediat
kill
c
bcll
cell
investig
whether
could
induc
adcc
c
bcll
cell
obtain
peripher
blood
sampl
bcll
patient
vitro
lactat
dehydrogenas
ldh
releas
assay
perform
coincub
bcll
target
cell
peripher
blood
mononuclear
cell
pbmc
healthi
donor
presenc
differ
antibodi
result
show
control
antibodi
could
mediat
adcc
dosedepend
manner
fig
next
vivo
examin
bcll
cell
kill
perform
c
bcll
cell
fig
inject
human
natur
killer
nk
cell
nsg
mice
intraven
confirm
whether
could
function
deplet
c
bcll
cell
gener
doubl
mutant
bind
either
fcgr
vivo
examin
circul
mous
blood
harvest
circul
cell
detect
fac
result
fig
show
c
bcll
cell
deplet
vivo
mice
mice
treat
control
fcmutat
contrast
c
patient
patient
show
deplet
bcll
cell
fig
taken
togeth
demonstr
adccand
cdcmediat
kill
c
cell
c
bcll
cell
vitro
vivo
studi
sought
human
murin
idiotop
antibodi
uniqu
bind
properti
potenti
broad
clinic
applic
studi
human
mice
demonstr
abl
select
deplet
c
b
cell
lead
prolong
loss
serum
igm
igg
studi
success
human
achiev
use
silico
model
approach
combin
structur
aid
antibodi
design
two
version
human
result
improv
bind
affin
compar
parent
compar
vitro
biolog
studi
adcc
cdc
activ
prove
abil
kill
c
cell
c
bcll
cell
irrespect
divers
light
chain
pair
fig
develop
de
novo
antibodi
homologybas
structur
abinitio
gener
antibodi
homolog
model
wam
program
provid
us
canon
structur
approach
use
uniform
conform
sampl
combin
iter
congen
algorithm
visual
deepview
predict
conform
side
chain
loop
yield
energet
minim
conform
model
noncanon
loop
region
structur
protein
data
bank
addit
model
energi
minim
sort
root
mean
squar
deviat
screen
advantag
sequencebas
design
reveal
potenti
steric
clash
distort
geometri
human
homolog
model
ideal
led
human
homolog
model
appropri
scaffold
conform
compat
engraft
cdr
retain
affin
similar
equival
mous
antibodi
studi
sequencebas
homolog
approach
suffici
gener
ideal
human
antibodi
result
complet
lost
bind
affin
overcom
problem
use
cdr
graft
combin
certain
conserv
key
residu
creat
two
human
version
via
select
suitabl
scaffold
surround
cdr
consequ
human
antibodi
reveal
increas
bind
affin
fold
slower
rate
parent
molecul
addit
scfvfc
exhibit
higher
affin
compar
scfvfc
ighvencod
immunoglobulin
fig
well
known
affin
loss
frequent
side
effect
human
howev
data
demonstr
multiparamet
model
strategi
result
success
human
higher
affin
current
smallanim
model
limit
use
analyz
therapeut
effect
antibodi
treatment
tumorassoci
antigen
express
tumor
cell
develop
antibodi
treatment
bcll
experiment
evalu
specif
antiidiotyp
therapi
vivo
even
challeng
due
low
percentag
id
c
human
b
cell
studi
util
two
differ
human
mous
model
evalu
human
mab
reconstruct
natur
human
b
cell
repertoir
mice
employ
gtl
mous
model
util
human
fetal
liver
thymu
tissu
nsg
background
strain
addit
c
haematopoiet
stem
cell
support
develop
immun
system
capabl
develop
robust
adapt
b
cell
respons
model
allow
us
use
mab
monitor
reconstruct
c
popul
bcrbear
b
cell
util
allel
germlin
gene
donor
c
stem
cell
encod
copi
germlin
gene
chromosom
gene
duplic
delet
lead
proport
variat
percentag
b
cell
circul
repertoir
respect
demonstr
rapid
effici
deplet
c
bcrbear
b
cell
result
markedli
reduc
human
igg
igm
extend
period
time
mechan
antiidiotyp
deplet
mous
model
presum
mediat
adcc
mous
myeloid
cell
demonstr
human
mab
addit
complement
compon
also
defect
level
cdc
may
still
occur
could
lead
deplet
c
b
cell
second
mous
model
bcll
directli
coinject
nsg
mice
bcll
patient
pbmc
almost
entir
compos
malign
clone
data
shown
due
littl
bcll
cell
fig
c
nk
cell
healthi
donor
deplet
c
malign
b
cell
evalu
hour
later
earli
time
point
chosen
sever
reason
includ
limit
number
bcll
cell
inject
mice
lower
mous
model
expect
rapid
kill
nk
cell
wellknown
limit
longterm
viabil
malign
cell
mice
nsg
model
may
improv
upon
report
bagnara
use
patient
pbmc
instead
purifi
b
cell
togeth
allogen
antigenpres
cell
author
abl
demonstr
bcll
prolifer
vivo
sever
doubl
mediat
prolifer
autolog
c
cell
activ
respons
alloantigen
bcll
cell
ultim
die
mice
sever
week
author
note
robust
bcll
prolifer
surviv
mous
spleen
compar
peripher
blood
find
seen
investig
also
evid
prolifer
center
format
cell
around
follicular
structur
addit
allogen
human
nk
cell
c
antigenpres
cell
model
other
use
may
provid
opportun
improv
evalu
mab
addit
patient
sampl
patient
bcll
b
cell
malign
remain
incur
current
avail
therapi
therefor
discoveri
novel
agent
treat
disord
urgent
need
use
antiidiotyp
mab
anticanc
agent
new
concept
gain
wide
accept
part
due
success
panimmunodeplet
mab
rituximab
alemtuzumab
percept
crossreact
idiotyp
conserv
malign
b
cell
differ
patient
b
cell
tumor
target
specif
antibodi
idiotop
encod
uniqu
surfac
immunoglobulin
activ
vaccin
follicular
lymphoma
patient
id
protein
tumor
shown
promis
effect
particularli
patient
develop
antiid
antibodi
respons
new
era
precis
cancer
medicin
immunotherapi
may
abl
fill
void
bcll
patient
select
deplet
c
bcrexpress
leukem
cell
treatment
goal
may
also
serv
altern
target
immunotherapi
c
patient
may
suboptim
clinic
respons
rituximab
due
downregul
express
due
heterogen
express
addit
given
involv
germlin
gene
sever
disord
involv
pathophysiolog
bcell
clonal
expans
includ
idiopath
thrombocytopen
purpura
mix
cryoglobulinemia
hepat
c
virusinduc
b
cell
clonal
disord
broader
rang
potenti
therapeut
applic
human
antiidiotyp
mab
investig
variant
idiotyp
antibodi
control
antibodi
produc
describ
previous
briefli
scfvfc
construct
clone
scfv
vector
frame
human
fc
region
without
domain
gener
clone
heavi
chain
variabl
region
vh
light
chain
variabl
region
vl
vector
fcmutat
construct
mutat
domain
antibodi
scfvfc
produc
cell
harvest
supernat
hybridoma
antibodi
purifi
protein
sepharos
affin
chromatographi
ge
healthcar
newark
nj
addit
scfv
clone
ctermin
histidin
tag
c
bacteri
express
vector
novagen
madison
wi
express
e
coli
novagen
purifi
supernat
lyse
cell
use
nickel
affin
chromatographi
via
aktapurifi
fplc
ge
healthcar
construct
human
gtl
mous
model
verif
vivo
activ
use
flow
cytometri
human
mice
construct
femal
nsg
mice
nodcgprkdc
scid
szj
jackson
laboratori
bar
harbor
describ
previous
subleth
whole
bodi
irradi
rad
gammacel
exactor
best
theratron
ottawa
canada
inject
c
haematopoiet
stem
cell
intraven
implant
mm
piec
human
fetal
thymu
liver
tissu
kidney
capsul
cohort
produc
tissu
singl
donor
c
hsc
isol
remain
portion
fetal
liver
use
antihuman
microbead
miltenyi
auburn
ca
puriti
determin
flow
cytometri
stain
miltenyi
engraft
mice
hous
biosafeti
condit
provid
autoclav
food
water
supplement
baytril
bayer
shawne
mission
ks
anim
experi
approv
institut
anim
care
research
committe
offic
human
subject
research
danafarb
cancer
institut
boston
week
postengraft
level
human
immun
reconstitut
measur
flow
cytometri
gtl
mice
randomli
assign
differ
group
treat
recombin
human
ligand
maintain
b
cell
popul
mice
addit
treat
presenc
absenc
mg
control
antibodi
intraven
inject
mice
bled
postinject
blood
sampl
centrifug
separ
plasma
fraction
cell
pellet
treat
ammonium
chlorid
ack
lyse
solut
life
technolog
enrich
pbmc
pbmc
mous
plasma
stain
fluorochromeconjug
antibodi
differ
cell
surfac
marker
follow
multicolor
flow
cytometri
use
lsrii
bd
bioscienc
san
jose
ca
follow
fluorochromeconjug
antibodi
use
antihuman
clone
pe
ebiosci
san
diego
ca
conjug
use
pierc
fitc
antibodi
label
kit
thermo
scientif
hudson
nh
gate
perform
viabl
lymphoid
cell
base
forward
side
scatter
profil
total
cell
stain
cell
analyz
within
lymphoid
gate
comparison
percentag
human
c
endogen
mous
c
perform
measur
level
immun
reconstitut
gtl
mice
marker
use
analyz
differ
human
blymphocyt
subset
background
stain
determin
use
correspond
isotyp
control
stain
cell
isol
nonengraft
anim
data
analyz
use
flowjo
version
tree
star
ashland
bind
activ
variant
includ
test
compar
use
cognat
antibodi
chosen
antigen
crossreact
idiotop
use
sequenc
germlin
configur
biotinyl
done
commerci
biotinyl
kit
pierc
elisa
analysi
perform
briefli
mgml
coat
maxisorp
plate
incub
overnight
c
unbound
protein
wash
away
pbst
pb
block
milk
hour
c
dilut
biotinyl
scfvfc
format
ad
well
incub
c
hour
plate
wash
pbst
ad
streptavidinhrp
incub
c
minut
result
measur
use
elisa
reader
develop
tetramethylbenzidin
solut
human
igg
igm
elisa
plate
coat
overnight
c
captur
antibodi
mgml
develop
detect
antibodi
antihuman
igm
igg
bethyl
lab
conjug
hrp
bind
scfvfc
scfv
compar
use
surfac
plasmon
reson
instrument
biacor
optic
biosensor
biacor
ab
uppsala
sweden
experi
perform
c
hbsp
buffer
mm
nacl
mm
hepe
surfact
mm
edta
briefli
ctermin
histidinetag
scfv
first
immobil
nta
sensor
chip
around
ru
captur
level
inject
variou
concentr
nm
via
singl
cycl
kinet
wizard
program
captur
surfac
regener
use
edta
follow
inject
run
buffer
doubl
refer
subtract
data
perform
correct
buffer
contribut
instrument
signal
nois
ratio
initi
subtract
kinet
analysi
data
perform
use
biaevalu
softwar
version
biacor
ab
assum
simpl
analyt
bind
model
msd
plate
coat
overnight
c
ml
mg
ml
pb
coat
plate
wash
block
ml
bsa
pb
c
h
scfv
phagemid
dilut
milk
pbst
ad
well
plate
incub
c
h
plate
wash
three
time
pbst
incub
ml
dilut
mab
mgml
c
h
anoth
wash
step
read
buffer
ad
electrochemiluminesc
measur
msd
sector
imag
cognat
antibodi
irrelev
control
antibodi
construct
express
vector
phage
scfv
antibodi
insert
leader
peptid
lp
fc
region
human
molecul
fc
domain
link
infram
short
segment
extracellular
domain
follow
respect
transmembran
domain
cytoplam
domain
incorpor
motif
form
sequenc
report
gene
ireszsgreen
construct
vector
cell
transfect
dna
encod
plasmid
hour
post
transfect
express
cell
analyz
fluoresc
microscop
flow
cytometri
use
apcconjug
antihuman
igg
biolegend
san
diego
ca
antibodi
zsgreen
posit
cell
sort
via
fac
target
cell
ldh
releas
assay
describ
previous
briefli
cell
use
target
cell
cellswel
incub
medium
contain
rabbit
serum
complement
cedarlan
laboratori
hornbi
ontario
canada
absenc
presenc
hour
incub
supernat
harvest
measur
use
nonradioact
cytotox
assay
kit
promega
madison
wi
nm
adcc
human
pbmc
use
effector
cell
incub
target
cell
cellswel
cell
plate
plate
incub
antibodi
differ
concentr
effector
cell
ad
effector
target
et
ratio
hour
incub
c
supernat
harvest
detect
ldh
releas
assay
vivo
activ
xenogen
bcll
patient
eightweekold
nsg
mice
receiv
pbmc
bcll
patient
human
natur
killer
nk
cell
intraven
inject
pbmc
bcll
patient
consent
describ
isol
ficollpaqu
plu
ge
healthcar
life
scienc
pittsburgh
pa
nk
cell
isol
use
easysep
tm
human
nk
cell
enrich
kit
stemcel
technolog
vancouv
british
columbia
canada
mice
treat
mgkg
control
mutat
version
mutat
fc
domain
intraven
hour
mous
blood
sampl
harvest
stain
includ
human
analyz
flow
cytometri
data
analyz
use
oneway
anova
twosid
unpair
student
ttest
differ
consid
statist
signific
p
valu
indic
p
respect
valu
bar
repres
mean
standard
deviat
sd
potenti
conflict
interest
disclos
